Inhibición de puntos de control: el tratamiento actual del carcinoma de células renales

Autores/as

  • Juan Esteban García-Robledo Mayo Clinic, Phoenix, Arizona, United States of America.
  • Herney Andrés García-Perdomo Division of Urology/Uro-oncology, Department of Surgery, School of Medicine, Universidad del Valle, Cali, Colombia.

DOI:

https://doi.org/10.48193/revistamexicanadeurologa.v82i2.839

Palabras clave:

inmunoterapia, , carcinoma de células renales, punto de control inmunitario, supervivencia global

Resumen

La vigilancia inmunológica es una de las características más importantes del cáncer. En la última década se han desarrollado muchos avances en el tratamiento del cáncer, muchos de ellos relacionados con el uso del sistema inmunológico. El carcinoma de células renales es el tipo de cáncer de riñón más frecuente seguido del carcinoma urotelial. Durante años, el tratamiento del Carcinoma de Células Renales ha sido conflictivo ya que estos tumores no responden bien a la quimioterapia y han demostrado ser susceptibles a inmunoterapias como el interferón y la interleucina 2. El descubrimiento de los puntos de control inmunitarios y su posible papel en el tratamiento del cáncer llevó a la síntesis de nuevos fármacos que pueden dirigirse e inhibir la interacción de ciertas moléculas que son importantes para la homeostasis inmunológica. En esta revisión concisa, resumimos la evidencia relacionada con la inhibición del punto de control inmunitario para el tratamiento del carcinoma de células renales, especialmente para el carcinoma metastásico de células renales.

Citas

Rübben A, Araujo A. Cancer heterogeneity: converting a limitation into a source of biologic information. Journal of Translational Medicine. 2017;15(1):190. doi: https://doi.org/10.1186/s12967-017-1290-9

Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell. 2011;144(5):646–74. doi: https://doi.org/10.1016/j.cell.2011.02.013

Falzone L, Salomone S, Libra M. Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium. Front Pharmacol. 2018;9:1300. doi: https://doi.org/10.3389/fphar.2018.01300

Lu M, Su Y. Immunotherapy in non-small cell lung cancer: The past, the present, and the future. Thoracic Cancer. 2019;10(4):585–6. doi: https://doi.org/10.1111/1759-7714.13012

Domingues B, Lopes JM, Soares P, Pópulo H. Melanoma treatment in review. ITT. 2018;7:35–49. doi: https://doi.org/10.2147/ITT.S134842

Lugowska I, Teterycz P, Rutkowski P. Immunotherapy of melanoma. Contemp Oncol (Pozn). 2018;22(1A):61–7. doi: https://doi.org/10.5114/wo.2018.73889

Tung I, Sahu A. Immune Checkpoint Inhibitor in First-Line Treatment of Metastatic Renal Cell Carcinoma: A Review of Current Evidence and Future Directions. Front Oncol. 2021;11:707214. doi: 10.3389/fonc.2021.707214

Pan R-Y, Chung W-H, Chu M-T, Chen S-J, Chen H-C, Zheng L, et al. Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens. Journal of Immunology Research. 2018;e4325874. doi: https://doi.org/10.1155/2018/4325874

Ribatti D. The concept of immune surveillance against tumors: The first theories. Oncotarget. 2016;8(4):7175–80. doi: https://doi.org/10.18632/oncotarget.12739

Nowell PC. The clonal evolution of tumor cell populations. Science. 1976;194(4260):23–8. doi: https://www.science.org/doi/10.1126/science.959840

Paluch C, Santos AM, Anzilotti C, Cornall RJ, Davis SJ. Immune Checkpoints as Therapeutic Targets in Autoimmunity. Frontiers in Immunology. 2018;9. doi: https://doi.org/10.3389/fimmu.2018.02306

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. doi: https://doi.org/10.3322/caac.21442

Protzel C, Maruschke M, Hakenberg OW. Epidemiology, Aetiology, and Pathogenesis of Renal Cell Carcinoma. European Urology Supplements. 2012;11(3):52–9. doi: https://doi.org/10.1016/j.eursup.2012.05.002

Pal SK, Ghate SR, Li N, Swallow E, Peeples M, Zichlin ML, et al. Real-World Survival Outcomes and Prognostic Factors Among Patients Receiving First Targeted Therapy for Advanced Renal Cell Carcinoma: A SEER-Medicare Database Analysis. Clin Genitourin Cancer. 2017;15(4):e573–82. doi: https://doi.org/10.1016/j.clgc.2016.12.005

Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. 1996;335(12):865–75. doi: https://doi.org/10.1056/nejm199609193351207

Nazha S, Tanguay S, Kapoor A, Jewett M, Kollmannsberger C, Wood L, et al. Use of Targeted Therapy in Patients with Metastatic Renal Cell Carcinoma: Clinical and Economic Impact in a Canadian Real-Life Setting. Current Oncology. 2018;25(6):576–84. doi: https://doi.org/10.3747/co.25.4103

Patard J-J, Kim HL, Lam JS, Dorey FJ, Pantuck AJ, Zisman A, et al. Use of the University of California Los Angeles Integrated Staging System to Predict Survival in Renal Cell Carcinoma: An International Multicenter Study. JCO. 2004;22(16):3316–22. doi: https://doi.org/10.1200/jco.2004.09.104

Ridge CA, Pua BB, Madoff DC. Epidemiology and Staging of Renal Cell Carcinoma. Semin intervent Radiol. 2014;31(01):003–8. doi: https://doi.org/10.1055/s-0033-1363837

Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Annals of Oncology. 2019;30(5):706–20. doi: https://doi.org/10.1093/annonc/mdz056

Freed SZ, Halperin JP, Gordon M. Idiopathic Regression of Metastases from Renal Cell Carcinoma. Journal of Urology. 1977;118(4):538–42. doi: https://doi.org/10.1016/S0022-5347(17)58099-4

Jilaveanu LB, Shuch B, Zito CR, Parisi F, Barr M, Kluger Y, et al. PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases. J Cancer. 2014;5(3):166–72. doi: https://doi.org/10.7150/jca.8167

Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, et al. Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer. New England Journal of Medicine. 1985;313(23):1485–92. doi: https://doi.org/10.1056/nejm198512053132327

Coppin C, Porzsolt F, Autenrieth M, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database of Systematic Reviews. 2004;(3). doi: https://doi.org/10.1002/14651858.CD001425.pub2

Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, et al. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A. 2004;101(49):17174–9. doi: https://doi.org/10.1073/pnas.0406351101

Zong Sheng Guo. The 2018 Nobel Prize in medicine goes to cancer immunotherapy. BMC Cancer. 2018 Nov 12;18(1):1086. doi: https://doi.org/10.1186/s12885-018-5020-3

Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 1995;270(5238):985–8. doi: https://doi.org/10.1126/science.270.5238.985

Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995;3(5):541–7. doi: https://doi.org/10.1016/1074-7613(95)90125-6

Klocke K, Sakaguchi S, Holmdahl R, Wing K. Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood. Proceedings of the National Academy of Sciences. 2016;113(17):E2383–92. doi: https://doi.org/10.1073/pnas.1603892113

Mitsuiki N, Schwab C, Grimbacher B. What did we learn from CTLA-4 insufficiency on the human immune system? Immunol Rev. 2019;287(1):33–49. doi: https://doi.org/10.1111/imr.12721

Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proceedings of the National Academy of Sciences. 2002;99(19):12293–7. doi: https://doi.org/10.1073/pnas.192461099

Nishimura H, Minato N, Nakano T, Honjo T. Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses. Int Immunol. 1998;10(10):1563–72. doi: 10.1093/intimm/10.10.1563

Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence. Cancers. 2020;12(3):738. doi: https://doi.org/10.3390/cancers12030738

Krabbe L-M, Bagrodia A, Margulis V, Wood CG. Surgical Management of Renal Cell Carcinoma. Semin intervent Radiol. 2014;31(01):027–32. doi: https://doi.org/10.1055/s-0033-1363840

Posadas EM, Limvorasak S, Figlin RA. Targeted therapies for renal cell carcinoma. Nat Rev Nephrol. 2017 Aug;13(8):496–511. doi: https://doi.org/10.1038/nrneph.2017.82

Tran J, Ornstein MC. Clinical Review on the Management of Metastatic Renal Cell Carcinoma. JCO Oncology Practice. 2022;18(3):187–96. doi: https://doi.org/10.1200/op.21.00419

Powles T, Albiges L, Staehler M, Bensalah K, Dabestani S, Giles RH, et al. Updated European Association of Urology Guidelines: Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer. European Urology. 2018 1;73(3):311–5. doi: https://doi.org/10.1016/j.eururo.2017.11.016

Cella D, Beaumont JL. Pazopanib in the treatment of advanced renal cell carcinoma. Ther Adv Urol. 2016;8(1):61–9. doi: https://doi.org/10.1177/1756287215614236

Gross-Goupil M, Kwon TG, Eto M, Ye D, Miyake H, Seo SI, et al. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial. Annals of Oncology. 2018;29(12):2371–8. doi: https://doi.org/10.1093/annonc/mdy454

Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma. New England Journal of Medicine. 2007;356(2):125–34. doi: https://doi.org/10.1056/nejmoa060655

Kollmannsberger C, Soulieres D, Wong R, Scalera A, Gaspo R, Bjarnason G. Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Canadian Urological Association Journal. 2007;1(2S). [accessed 25 Apr 2022] Available from: https://dx.doi.org/10.5489%2Fcuaj.67

Ko JJ, Xie W, Kroeger N, Lee J, Rini BI, Knox JJ, et al. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. The Lancet Oncology. 2015;16(3):293–300. doi: https://doi.org/10.1016/S1470-2045(14)71222-7

Malouf GG, Flippot R, Khayat D. Therapeutic Strategies for Patients With Metastatic Renal Cell Carcinoma in Whom First-Line Vascular Endothelial Growth Factor Receptor–Directed Therapies Fail. JOP. 2016 May;12(5):412–20. doi: https://doi.org/10.1200/jop.2016.011809

Graham J, Heng DYC, Brugarolas J, Vaishampayan U. Personalized Management of Advanced Kidney Cancer. Am Soc Clin Oncol Educ Book. 2018;38:330–41. doi: https://doi.org/10.1200/edbk_201215

Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. New England Journal of Medicine. 2018;378(14):1277–90. doi: https://doi.org/10.1056/nejmoa1712126

Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019;380(12):1116–27. doi: https://doi.org/10.1056/nejmoa1816714

Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New England Journal of Medicine. 2019 Mar 21;380(12):1103–15. doi: https://doi.org/10.1056/nejmoa1816047

Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, et al. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New England Journal of Medicine. 2021 Mar 4;384(9):829–41. doi: https://doi.org/10.1056/nejmoa2026982

Motzer R, Alekseev B, Rha S-Y, Porta C, Eto M, Powles T, et al. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. New England Journal of Medicine. 2021;384(14):1289–300. doi: https://doi.org/10.1056/nejmoa2035716

Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. New England Journal of Medicine. 2015;373(19):1803–13. doi: https://dx.doi.org/10.1056%2FNEJMoa1510665

Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. The Lancet. 2019;393(10189):2404–15. doi: https://doi.org/10.1016/S0140-6736(19)30723-8

Descargas

Publicado

2022-05-11

Número

Sección

Artículos de revisión